Patents Issued in March 7, 2017
  • Patent number: 9585837
    Abstract: The present invention relates to thermally, stable oil-in-water emulsions comprising an oil comprising a polyunsaturated fatty acid, water, an emulsifier, and a water-soluble stabilizer, and processes for preparing the thermally stable oil-in-water emulsions. The thermally stable oil-in-water emulsions remain flowable at a temperature of ?40° C., and are free from a variation in particle size after 9 months in storage at a temperature of ?40° C. to ?15° C.
    Type: Grant
    Filed: April 6, 2011
    Date of Patent: March 7, 2017
    Assignee: DSM IP ASSETS B.V.
    Inventors: Jimbin Mai, Micah Hazzy Needham, Gang Su, Wei Wang-Nolan, Chia-Ping Charles Hsu
  • Patent number: 9585838
    Abstract: Multivesicular liposomes are prepared at commercial scales by combining a first w/o emulsion with a second aqueous solution to form a w/o/w emulsion using a static mixer. Solvent is removed from the resulting emulsion to form multivesicular liposome-containing compositions. Further optional process steps include primary filtration and secondary cross-flow filtration. The products produced according to the processes of the invention can be produced through a series of aseptic steps.
    Type: Grant
    Filed: February 25, 2007
    Date of Patent: March 7, 2017
    Assignee: Pacira Pharmaceuticals, Inc.
    Inventors: Hartoun Hartounian, Dagmar Meissner, Clint B. Pepper
  • Patent number: 9585839
    Abstract: The invention provides a method of making a composition for inhalation which includes the step of mixing particles of additive material having a diameter of not more than 2 ?m with active particles, wherein the additive material is suitable for promoting the dispersal of active particles upon aerolization of a dry powder in a dry powder inhaler.
    Type: Grant
    Filed: October 10, 2013
    Date of Patent: March 7, 2017
    Assignee: VECTURA LIMITED
    Inventors: John Nicholas Staniforth, David Alexander Vodden Morton
  • Patent number: 9585840
    Abstract: Nanoparticles disclosed in the invention comprise a dextran-coated crystalline structure of cerium oxide wherein tetravalent Ce4+ predominates over trivalent Ce3+ and wherein said nanoparticles have a diameter of approximately from 3 to 5 nm. The nanoparticles exhibit both superoxide dismutase activity and catalase activity in an environment having a substantially neutral or acidic pH. The nanoparticles may be used to make and may be contained in a medication. The subject nanoparticles are useful in a method of promoting a cytotoxic anti-invasive effect on squamous tumor cells and inhibit tumor invasiveness.
    Type: Grant
    Filed: July 13, 2012
    Date of Patent: March 7, 2017
    Assignee: University of Central Florida Research Foundation, Inc.
    Inventors: Peter Brenneisen, Sudipta Seal, Ajay Karakoti
  • Patent number: 9585841
    Abstract: Provided herein are methods comprising providing a tyrosine derivative and a solid particulate material (and, optionally, melanin) and applying force to said tyrosine derivative and said solid particulate material for a time and under conditions effective to impregnate at least one of said tyrosine derivative and said solid particulate material with the other of said tyrosine derivative and said solid particulate material. The invention also provides compositions comprising at least one of a tyrosine derivative impregnated with a solid particulate material and a solid particulate material impregnated with a tyrosine derivative.
    Type: Grant
    Filed: October 24, 2013
    Date of Patent: March 7, 2017
    Assignee: Tyme, Inc.
    Inventor: Steven Hoffman
  • Patent number: 9585842
    Abstract: The present invention is directed to a pharmaceutical composition comprising guanfacine or a salt thereof in nanoparticle form and at least one non-pH dependent sustained release agent. The present invention further is directed to a method of producing said nanoparticles and to nanoparticles obtained by this method.
    Type: Grant
    Filed: April 28, 2014
    Date of Patent: March 7, 2017
    Assignee: SALMON PHARMA GMBH
    Inventors: Akif Emre Tuereli, Bernd Baumstuemmler, Richard Ammer
  • Patent number: 9585843
    Abstract: The present invention provides a simple and improved dose form that is capable of providing a controlled release of GABAB receptor agonist contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to GABAB receptor agonist.
    Type: Grant
    Filed: April 19, 2016
    Date of Patent: March 7, 2017
    Assignee: Osmotica Kereskedelmi es Szoloaltato Kft
    Inventors: Glenn A. Meyer, Cristian R. Franco, Gustavo A. Fischbein, Alejandro A. Aguilar, Claude E. Wright
  • Patent number: 9585844
    Abstract: An oral composition comprising minicapsules wherein the minicapsules comprise one or more therapeutic or prophylactic substances in a liquid, semi-liquid, or solid core. The minicapsules have release profiles to release the substance in an active form at one or more sites along the gastro-intestinal tract to maximize absorption and/or therapeutic efficiency.
    Type: Grant
    Filed: June 29, 2015
    Date of Patent: March 7, 2017
    Assignee: Sigmoid Pharma Limited
    Inventor: Ivan Coulter
  • Patent number: 9585845
    Abstract: A pharmaceutical composition, including: an active ingredient-loaded pellet core and a coating layer. The active ingredient of the pellet core is oseltamivir or a pharmaceutically acceptable salt thereof. The active ingredient accounts for between 10 and 40 wt. % of the total weight of the pharmaceutical composition. The coating layer includes a polyacrylic acid resin IV and accounts for between 1 and 50 wt. % of the total weight of the pharmaceutical composition. The pharmaceutical composition has a diameter of between 0.10 and 0.50 mm.
    Type: Grant
    Filed: January 11, 2016
    Date of Patent: March 7, 2017
    Assignee: Zhongshuai Pharmaceutical Sci & Tech Co., Ltd.
    Inventors: Weidong Sun, Fengxiao Ren
  • Patent number: 9585846
    Abstract: The present invention relates to an anti-microbial composition and method of use thereof. In particular, the present invention relates to an anti-microbial composition comprising farnesol and cetrimide.
    Type: Grant
    Filed: September 8, 2014
    Date of Patent: March 7, 2017
    Assignee: Wild Child
    Inventor: John Found
  • Patent number: 9585847
    Abstract: Small molecule xanthine oxidase inhibitors are provided, as well as methods for their use in treating gout or hyperuricemia.
    Type: Grant
    Filed: September 10, 2014
    Date of Patent: March 7, 2017
    Assignee: Baylor College of Medicine
    Inventors: Changyi Chen, Jian-Ming Lu, Qizhi Yao
  • Patent number: 9585848
    Abstract: Small molecule xanthine oxidase inhibitors are provided, as well as methods for their use in treating gout or hyperuricemia.
    Type: Grant
    Filed: September 10, 2014
    Date of Patent: March 7, 2017
    Assignee: Baylor College of Medicine
    Inventors: Changyi Chen, Jian-Ming Lu, Qizhi Yao
  • Patent number: 9585849
    Abstract: A method for the prevention or treatment of Influenza virus infection or Adenovirus infection by administering an effective amount of a compound of Formula (I), Formula (II), or similar compound to an individual in need is provided.
    Type: Grant
    Filed: April 17, 2007
    Date of Patent: March 7, 2017
    Assignee: The Burlington HC Research Group, Inc.
    Inventors: Dale M. Walker, Adriana Elisa Kajon, Vernon E. Walker
  • Patent number: 9585850
    Abstract: The present invention is directed to a method of treating Parkinson's disease using arylcyclopropylamine compounds. The arylcyclopropylamine compounds have the following formula wherein R1, R2, R3, R4, R5 and R6 are described herein.
    Type: Grant
    Filed: October 14, 2014
    Date of Patent: March 7, 2017
    Assignee: Duke University
    Inventors: Dewey G. McCafferty, Julie A. Pollock, David M. Gooden, Marc G. Caron, Raul R. Gainetdinov, Tatyana D. Sotnikova
  • Patent number: 9585851
    Abstract: Methods are provided for treating a subject for a condition caused by an abnormality in the subject's autonomic nervous system. In accordance with the subject methods, at least a portion of a subject's autonomic nervous system is pharmacologically modulated with at least one beta-blocker in a manner that is effective to treat the subject for the condition. The subject methods find use in the treatment of a variety of different conditions, where such conditions include various disease conditions. Also provided are systems and kits for use in practicing the subject methods.
    Type: Grant
    Filed: April 24, 2012
    Date of Patent: March 7, 2017
    Assignee: Palo Alto Investors
    Inventors: Anthony Joonkyoo Yun, Patrick Yuarn-Bor Lee
  • Patent number: 9585852
    Abstract: The invention is dietary supplements, nutraceutical compositions, medical foods, and animal feeds that have cytoprotective (cell and tissue protection) and health promoting effects. The compositions contain a high dose range of agmatine and nutraceutical acceptable salts thereof as dietary fortification for providing effective long-term cytoprotection and affording for soft stool. The compositions may contain agmatine alone or in combination with other dietary ingredients having health promoting effects. The compositions can be prepared with dietary accepted excipients and compatible forms of carriers, including but not limited to, powders, tablets, capsules, controlled release carriers, lozenges and chewable preparations, liquid suspensions, suspensions in an edible supporting matrix or foodstuff and oral rehydration solutions, to enable consumption of said compositions.
    Type: Grant
    Filed: December 1, 2014
    Date of Patent: March 7, 2017
    Inventors: Gad Gilad, Varda Gilad
  • Patent number: 9585853
    Abstract: The invention provides 1,3-diphenylprop-2-en-1-one derivatives and pharmaceutical compositions comprising the same for treating liver disorders, in particular those requiring the reduction of plasma level of biochemical markers such as aminotransferases. The 1,3-diphenylprop-2-en-1-one derivatives of General Formula (I) have hepatoprotective properties and can be used in methods for treating liver disorders involving the pathological disruption, inflammation, degeneration, and/or proliferation of liver cells, such as liver fibrosis or fatty liver disease.
    Type: Grant
    Filed: November 5, 2015
    Date of Patent: March 7, 2017
    Assignee: GENFIT
    Inventors: Raphael Darteil, Rémy Hanf, Dean Hum, Ingrid Dufour
  • Patent number: 9585854
    Abstract: The invention relates to a new use of NAC in IVF, in a human or mammalian animal patient. In addition an effective dose regimen of NAC in IVF is proposed.
    Type: Grant
    Filed: November 6, 2013
    Date of Patent: March 7, 2017
    Assignee: IASOMAI AB
    Inventors: Thomas Lundeberg, Tiziana Parasassi, Eugenia Pittaluga, Roberto Brunelli
  • Patent number: 9585855
    Abstract: The present invention relates to methods of treating the side effects of a toxic medical therapy using nitrated lipids. In particular, the methods comprise the use of nitrated fatty acids or esters thereof to treat side effects, including organ system damage, caused by chemotherapy, radiotherapy, and the administration of other toxic agents.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: March 7, 2017
    Assignee: The University of Utah Research Foundation
    Inventor: Tianxin Yang
  • Patent number: 9585856
    Abstract: The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases.
    Type: Grant
    Filed: April 6, 2016
    Date of Patent: March 7, 2017
    Assignee: AMARIN PHARMACEUTICALS IRELAND LIMITED
    Inventors: Mehar Manku, Ian Osterloh, Pierre Wicker, Rene Braeckman, Paresh Soni
  • Patent number: 9585857
    Abstract: This invention relates to pharmaceutical composition and methods of using vitamin A and/or RARB agonist for the treatment or prevention of diseases or conditions associated with high fat diet and/or vitamin deficiency. After smoking, high fat diet is said to be the second most lethal habit, causing 300,000 deaths each year in the U.S. alone. High fat diet leads to many health problems, including obesity, stroke, cancer, high blood pressure, diabetes, osteoarthritis, rheumatoid arthritis, multiple sclerosis, heart disease, and diseases in other organs such as liver and kidney.
    Type: Grant
    Filed: January 17, 2014
    Date of Patent: March 7, 2017
    Assignee: Cornell University
    Inventors: Lorraine J Gudas, Yannick Benoit, Ronald Perez, Xiao-Han Tang, Steven Trasino
  • Patent number: 9585858
    Abstract: The present invention relates to a pharmaceutical composition containing 13 compounds: 1,3-diolein, 1-linolein-3-olein, 1,2-diolein, 1-olein-2-linolein, 1,2-dilinolein, trilinolein, 1-olein-2,3-dilinolein, 1-palmitin-2,3-dilinolein, 1,3-diolein-2-linolein, 1-palmitin-2-linolein-3-olein, 1,3-dipalmitin-2-linolein, triolein and 1-palmitin-2,3-diolein. The invention also relates to pharmaceutical preparations of this composition and the use thereof in the treatment of tumors and in the immuno-enhancement.
    Type: Grant
    Filed: June 8, 2015
    Date of Patent: March 7, 2017
    Assignee: ZHEJIANG KANGLAITE GROUP CO., LTD.
    Inventor: Dapeng Li
  • Patent number: 9585859
    Abstract: In various embodiments, the present invention provides methods of lowering triglycerides in subject on statin therapy and having baseline fasting triglycerides of about 200 mg/dl to less than 500 mg/dl, the methods comprising administering to the subject a composition comprising ethyl eicosapentaenoate.
    Type: Grant
    Filed: September 25, 2014
    Date of Patent: March 7, 2017
    Assignee: AMARIN PHARMACEUTICALS IRELAND LIMITED
    Inventors: Ian Osterloh, Pierre Wicker, Rene Braeckman, Paresh Soni, Mehar Manku
  • Patent number: 9585860
    Abstract: A method for treating eczema including the steps of applying an isothiocyanate functional surfactant to an area affected by eczema, wherein the isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant.
    Type: Grant
    Filed: October 21, 2014
    Date of Patent: March 7, 2017
    Assignee: The William M. Yavbrough Foundation
    Inventor: Michael E. Silver
  • Patent number: 9585861
    Abstract: Gold(III) complexes with mixed ligands as anticancer agents. The gold(III) cations are coordinated to bidentate ligands having diamino functional groups: a diaminocyclohexane ligand and a 1,3-propylenediamine ligand. The diaminocyclohexane ligand can exist in both cis- and trans- configurations, resulting in isomeric gold(III) complexes. Also described are pharmaceutical compositions incorporating the gold(III) complexes, methods of synthesis, methods of treating cancer and methods of inhibiting cancer cell proliferation and inducing cancer cell apoptosis.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: March 7, 2017
    Assignee: King Fahd University of Petroleum and Minerals
    Inventors: Said Al-Jaroudi, Muhammad Altaf, Abdulaziz Al-Saadi, Anvarhusein Abdulkadir Isab
  • Patent number: 9585862
    Abstract: The present invention relates to a rivastigmine-containing patch having improved storage stability and proper release property.
    Type: Grant
    Filed: May 21, 2012
    Date of Patent: March 7, 2017
    Assignee: SK CHEMICALS CO., LTD.
    Inventors: Yong-youn Hwang, Won-Jae Choi, Jae-Sun Kim, Won-No Youn, Yeo-Jin Park, Joon-gyo Oh, JongSeob Im
  • Patent number: 9585863
    Abstract: The present invention relates to a method of treating cataplexy in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of certain carbamate compounds.
    Type: Grant
    Filed: May 9, 2016
    Date of Patent: March 7, 2017
    Assignees: Jazz Pharmaceuticals International III Limited, SK Biopharmaceuticals Co., Ltd.
    Inventors: Moise A. Khayrallah, Gary Bream, Stephen E. Butts
  • Patent number: 9585864
    Abstract: This invention relates to a pharmaceutical formulation containing z-butylidenephthalide and a polymer, e.g., a polyanhydride. Also disclosed is use of this formulation to treat tumor.
    Type: Grant
    Filed: April 14, 2015
    Date of Patent: March 7, 2017
    Assignee: National Dong Hwa University
    Inventors: Tzyy-Wen Chiou, Horng-Jyh Harn, Shinn-Zong Lin
  • Patent number: 9585865
    Abstract: The present invention relates to the use of compounds which are capable of producing a cooling sensation when they are brought into contact with the human body. In particular, the present invention relates to the use of compounds modulating TRPM8, and optionally to the use of compounds selectively exhibiting agonist activity at the TRPM8 channel. Such compounds have applications in many fields, particularly in oral and personal hygiene products and foodstuffs, but also in pharmaceutical composition products, cosmetics, textile products and packaging products. The present invention further relates to products containing such compounds and to the medical use of such compounds.
    Type: Grant
    Filed: December 8, 2014
    Date of Patent: March 7, 2017
    Assignee: B.R.A.I.N. Biotechnology Research and Information Network AG
    Inventors: Michael Krohn, Holger Zinke
  • Patent number: 9585866
    Abstract: The present invention provides personal care compositions comprising a carrier and a mixture of essential oil components having specific levels of eucalyptol, terpene materials and auxiliary fragrance materials. The compositions herein gentle to skin and have a fragrance and activity similar if the composition were made using the pure extracted essential oil.
    Type: Grant
    Filed: March 4, 2015
    Date of Patent: March 7, 2017
    Assignee: The Procter & Gamble Company
    Inventor: Christine Marie Cahen
  • Patent number: 9585867
    Abstract: A method of humanely incapacitating or immobilizing a human or animal by providing a formulation including a cannabinoid rendering a recipient incapacitated or immobilized within a short period of time, and a delivery system which doses the recipient with the formulation resulting in a tetrahydrocannabinol blood level of above at least approximately 1-250 milligrams per milliliter of whole blood for incapacitation, or at least approximately 250-500 milligrams per milliliter of whole blood for immobilization, and below a dosage which causes irreparable harm to or the death of the recipient. Providing a delivery system to induce an incapacitating or immobilizing dose of the formulation at a distance. Providing a formulation including an antipsychotic to prevent or mitigate any violent psychosis of the recipient. Providing the formulation which induces a lethal cannabinoid blood level in the recipient which causes the death of the recipient within a humane period of time after formulation administration.
    Type: Grant
    Filed: August 6, 2015
    Date of Patent: March 7, 2017
    Inventor: Charles Everett Ankner
  • Patent number: 9585868
    Abstract: Presented herein are methods for treating diarrhea by administering to a patient in need thereof, an inhibitor of chloride-ion transport in an amount sufficient to treat diarrhea. Treatment of diarrhea includes the treatment of the diarrhea as well as the pain, abdominal discomfort and other symptoms associated with diarrhea. In one embodiment, the inhibitor of chloride-ion transport is crofelemer.
    Type: Grant
    Filed: January 15, 2015
    Date of Patent: March 7, 2017
    Assignee: NAPO PHARMACEUTICALS, INC.
    Inventors: William Forbes, Enoch Bortey, Steven King, Pravin Chaturvedi
  • Patent number: 9585869
    Abstract: Substituted 2-[2-(phenyl)ethylamino]alkaneamide derivatives of formula (I) wherein X, Y, Z, R, R1, R2, R3, R?3 R4, R5, R6, R7 have the meanings defined in the specification and pharmaceutically acceptable salts thereof, pharmaceutical compositions containing them as active ingredient and their use as sodium and/or calcium channel modulators useful in preventing, alleviating and curing a wide range of pathologies, including, but not limited to, neurological, cognitive, psychiatric, inflammatory, urogenital and gastrointestinal diseases, where the above mechanisms have been described as playing a pathological role.
    Type: Grant
    Filed: February 5, 2015
    Date of Patent: March 7, 2017
    Assignee: NEWRON PHARMACEUTICALS, S.P.A.
    Inventors: Piero Melloni, Alessandra Restivo, Emanuela Izzo, Simona Francisconi, Elena Colombo, Cibele Sabido-David
  • Patent number: 9585870
    Abstract: The present disclosure relates to the use of pharmaceutical agents to manipulate serotonin in animal mammary glands. Use of the serotonin agents results in increased PTHrP levels, resulting in the release of calcium from the bone, which improves lactation.
    Type: Grant
    Filed: January 25, 2013
    Date of Patent: March 7, 2017
    Assignees: UNIVERSITY OF CINCINNATI, WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Nelson Horseman, Laura Hernandez Baumgard
  • Patent number: 9585871
    Abstract: The present invention encompasses methods of using fexinidazole to treat and eliminate and/or cure L. infantum infections in canines.
    Type: Grant
    Filed: January 31, 2014
    Date of Patent: March 7, 2017
    Assignee: MERIAL, INC.
    Inventors: Matthias Pollmeier, Jeffrey Lynn Blair
  • Patent number: 9585872
    Abstract: Effective treatments of pain for extended periods of time are provided. Through the administration of an effective amount of clonidine at or near a target site, one can relieve pain caused by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discogenic back pain and joint pain, as well as pain that is incidental to surgery. When appropriate formulations are provided within biodegradable polymers, this relief can be continued for at least three days. In some embodiments, the relief can be for at least twenty-five days, at least fifty days, at least one hundred days, at least one hundred and thirty-five days or at least one hundred and eighty days.
    Type: Grant
    Filed: January 29, 2015
    Date of Patent: March 7, 2017
    Assignee: Warsaw Orthopedic, Inc.
    Inventors: John Myers Zanella, Christopher M. Hobot, Danielle L. Biggs, Katara Shaw, Phillip Edward McDonald, Vanja Margareta King, William F. McKay, Kathy L. Remsen
  • Patent number: 9585873
    Abstract: A method is described for the treatment of systemic diseases in cats. A composition is administered to a cat, where the composition includes a therapeutically effective amount of angiotensin II receptor 1 (AT-1) antagonist (sartan).
    Type: Grant
    Filed: June 2, 2014
    Date of Patent: March 7, 2017
    Assignee: Boehringer Ingelheim Vetmedica GmbH
    Inventors: Marcus Stark, Ulrike D. Sent, Ingo Lang
  • Patent number: 9585874
    Abstract: The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the compounds of formula I, and methods of using the compounds, salts and compositions in the treatment of various disorders associated with CRM1 activity.
    Type: Grant
    Filed: January 6, 2016
    Date of Patent: March 7, 2017
    Assignee: Karyopharm Therapeutics Inc.
    Inventors: Vincent P. Sandanayaka, Sharon Shechter, Sharon Shacham, Dilara McCauley, Erkan Baloglu
  • Patent number: 9585875
    Abstract: The invention relates to compounds acting as selective antagonists of Transient Receptor Potential cation channel subfamily M member 8 (TRPM8), and having formula (I). Said compounds are useful in the treatment of diseases associated with activity of TRPM8 such as pain, inflammation, ischaemia, neurodegeneration, stroke, psychiatric disorders, itch, irritable bowel diseases, cold induced and/or exhacerbated respiratory disorders and urological disorders.
    Type: Grant
    Filed: December 19, 2012
    Date of Patent: March 7, 2017
    Assignee: DOMPÉ FARMACEUTICI S.P.A.
    Inventors: Alessio Moriconi, Gianluca Bianchini, Sandro Colagioia, Laura Brandolini, Andrea Aramini, Chiara Liberati, Silvia Bovolenta
  • Patent number: 9585876
    Abstract: Compositions, methods, and kits useful for treating hyperlipidemic conditions are provided herein. Such compositions can contain synergizing amounts of nicotinic acid, nicotinamide riboside and/or nicotinic acid metabolites in combination with leucine and/or a leucine metabolite, with or without resveratrol.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: March 7, 2017
    Assignee: NUSIRT SCIENCES, INC.
    Inventors: Michael Zemel, Antje Bruckbauer
  • Patent number: 9585877
    Abstract: A method of administering an effective amount of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide, or a pharmaceutically acceptable salt thereof, to a patient in need thereof.
    Type: Grant
    Filed: May 6, 2013
    Date of Patent: March 7, 2017
    Assignee: Forum Pharmaceuticals, Inc.
    Inventors: Dana C. Hilt, Gerhard Koenig
  • Patent number: 9585878
    Abstract: This application provides for a method of increasing brain-derived neurotrophic factor (BDNF) serum level in a human subject comprising periodically administering to the subject an amount of laquinimod or pharmaceutically acceptable salt thereof effective to increase BDNF serum level in the human subject. The method can further comprise periodically administering to the subject an amount of a second BDNF-increasing agent. This application also provides for a method for treating a human subject suffering from a BDNF-related disease comprising periodically administering laquinimod or a pharmaceutically acceptable salt thereof in an amount effective to treat the human subject. This application additionally provides for use of laquinimod in the manufacture of a medicament for increasing BDNF serum level in a human subject. This application further provides for a pharmaceutical composition comprising an amount of laquinimod effective for use in increasing BDNF serum level in a human subject.
    Type: Grant
    Filed: August 9, 2010
    Date of Patent: March 7, 2017
    Assignee: TEVA PHARMACEUTICAL INDUSTRIES, LTD.
    Inventor: Liat Hayardeny
  • Patent number: 9585879
    Abstract: The present invention relates to heterocyclic substituted quinoline derivatives as allosteric inhibitors of the glycogen synthase kinase-3 (GSK-3) enzyme. Therefore, these compounds are useful for the manufacturing of a medicament designed for the treatment and/or prevention of diseases wherein GSK-3 is involved, such as neurodegenerative diseases, inflammatory diseases, cancer, diabetes, and to promote various regenerative processes.
    Type: Grant
    Filed: October 22, 2015
    Date of Patent: March 7, 2017
    Assignee: Consejo Superior de Investigaciones Cientificas (CSIC)
    Inventors: Ana Martinez Gil, Carmen Gil Ayuso-Gontan, Valle Palomo Ruiz, Concepcion Perez Martin, Daniel I. Perez Fernandez, Julio Alberto Reyes Rodriguez
  • Patent number: 9585880
    Abstract: The present invention relates to tertiary amines of formula (I) for use in therapy, particularly for use in treating cardiovascular disorders. The compounds have been found to regulate phospholamban phosphorylation by interfering with the A-kinase anchor protein 18delta (AKAP18?) binding to the PKA substrate phospholamban. The compounds share a tri(alkylaryl/alkylheteroaryl) amine structure.
    Type: Grant
    Filed: November 20, 2014
    Date of Patent: March 7, 2017
    Assignee: Universitetet I Oslo
    Inventors: Jo Klaveness, Kjetil Tasken
  • Patent number: 9585881
    Abstract: The present invention provides compounds of the general formula (I), their salts and N-oxides, and solvates and prodrugs thereof (wherein the substituents are as defined in the description). The compounds of the general formula (I) are inhibitors of factor XIa, and are useful in the prevention of and/or therapy for thromboembolic diseases.
    Type: Grant
    Filed: June 13, 2016
    Date of Patent: March 7, 2017
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Akira Imagawa, Takashi Kondo, Taihei Nishiyama, Steve Courtney, Chris Yarnold, Osamu Ichihara, Stuart Flanagan
  • Patent number: 9585882
    Abstract: In one aspect, the invention relates to compounds having the formula I: where R1, R2a, R2b, and R3-R6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.
    Type: Grant
    Filed: January 29, 2015
    Date of Patent: March 7, 2017
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Melissa Fleury, Anne-Marie Beausoliel, Adam D. Hughes, Daniel D. Long, Donna A. A. Wilton
  • Patent number: 9585883
    Abstract: Provided are novel pyrimidine dione compounds and pharmaceutically acceptable salts thereof, that are useful for the treatment of hypertrophic cardiomyopathy (HCM) and conditions associated with left ventricular hypertrophy or diastolic dysfunction. The synthesis and characterization of the compounds and pharmaceutically acceptable salts thereof, are described, as well as methods for treating HCM and other forms of heart disease.
    Type: Grant
    Filed: October 14, 2015
    Date of Patent: March 7, 2017
    Assignee: MYOKARDIA, INC.
    Inventors: Johan Oslob, Robert Anderson, Danielle Aubele, Marc Evanchik, Jonathan Charles Fox, Brian Kane, Puping Lu, Robert McDowell, Hector Rodriguez, Yonghong Song, Arvinder Sran
  • Patent number: 9585884
    Abstract: The present invention relates to new pyrimidinone inhibitors of lipoprotein-associated phospholipase A2 activity, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Grant
    Filed: December 16, 2013
    Date of Patent: March 7, 2017
    Assignee: Auspex Pharmaceuticals, Inc.
    Inventors: Tadimeti Rao, Chengzhi Zhang
  • Patent number: 9585885
    Abstract: [Problem] To provide a novel compound that exhibits an agonistic effect on dopamine D2 receptors. [Solution] The present invention provides a compound represented by the general formula (I): in which R1 is C1-6 alkyl or the like; R2 is hydrogen or the like; R3 and R4 are each hydrogen, C1-6 alkyl, R10R11N—C1-6 alkyl, aralkyl, or the like; R5 and R6 are hydrogen or the like; and R7 is hydrogen or the like, or a pharmaceutically acceptable salt thereof, a pharmaceutical compositions containing same and uses for said compound/salt and composition. The compounds of the present invention exhibit potent dopamine D2 receptor simulating activities and thus are useful as a treating or preventing agent for Parkinson's disease and the like.
    Type: Grant
    Filed: December 6, 2013
    Date of Patent: March 7, 2017
    Assignee: KISSEI PHARMACEUTICAL CO., LTD.
    Inventors: Toshihiro Nishimura, Yasunori Ueno, Kiyoshi Kasai, Masako Yoshida
  • Patent number: 9585886
    Abstract: This invention relates to pyrrolopyrimidine derivatives of formula (I): where R1, X, p, R4, R2 and R3 are as defined herein, and their use as pharmaceuticals.
    Type: Grant
    Filed: April 28, 2015
    Date of Patent: March 7, 2017
    Assignee: Calchan Limited
    Inventors: David R. Witty, David Norton, Jason Paul Tierney, Ghislaine Lorthioir, Mairi Sime, Karen Louise Philpott